Contents

Preface *Bernard Escudier and Martin Gore* vii

Acknowledgements and contributors viii

1. Epidemiology and aetiology *Börje Ljungberg*

1.1 Introduction 1
1.2 Incidence of RCC: changing trends 2
1.3 RCC prevalence 3
1.4 Changes in RCC mortality rates 5
1.5 Effect of age, race and gender 7
1.6 Aetiological factors 8

Conclusions 12
References 12

2. Molecular mechanisms *Eamonn Maher*

2.1 Introduction 16
2.2 Von Hippel–Lindau disease and the VHL/HIF pathway 17
2.3 The Krebs cycle and RCC 21
2.4 The mTOR pathway and *FLCN*, *PTEN* and *TSC1/2* genes 22
2.5 Type 1 PRCC and the *MET* proto-oncogene 25

Conclusions 26
References 26

3. Diagnosis and pathological features *Vincent Molinié, Mathilde Sibony, Jérôme Couturier and Annick Vieillefond*

3.1 Introduction 30
3.2 Clear-cell RCC 31
3.3 Multilocular cystic RCC 35
3.4 Papillary RCC 36
3.5 Oncocytomas 44
3.6 Chromophobe RCC 45
3.7 Hybrid chromophobe RCC and oncocytoma associated with BHD syndrome 46
3.8 Collecting duct and renal medullary carcinoma 47
3.9 Other miscellaneous RCCs 48
3.10 Prognostic factors 48

Conclusions 51
References 52

4. Surgery *Steffen Weikert and Kurt Miller*

4.1 Introduction 54
4.2 Preoperative assessment 55
4.3 Surgical techniques 55
4.4 Follow-up 65
4.5 Surgery for metastatic RCC 65

4.6 Alternative minimally invasive techniques: local ablative therapy 67
Conclusions 69
References 70

5. Systemic treatment for metastatic renal cell carcinoma *Sylvie Négrier and Viktor Grünwald*
5.1 Introduction 74
5.2 Immunotherapy 75
5.3 Targeted therapy 78
Conclusions 102
References 103

6. Sequential and combination systemic treatment *Sergio Bracarda*
6.1 Introduction 111
6.2 Combination treatment 113
6.3 Sequential treatment 120
6.4 Novel targets and new therapies: increased sequential/combination potential 126
Conclusions 126
References 127

7. Practice problems *Lynda Pyle and Tim Eisen*
7.1 Introduction 132
7.2 Toxicities associated with current systemic treatments 133
7.3 Management of toxicities 137
7.4 Other treatment considerations with targeted agents 147
7.5 Patient education and communication 149
7.6 Clinical benefit and quality of life 151
Conclusions 152
References 153

8. Algorithms for systemic treatment *Joaquim Bellmunt*
8.1 Introduction 155
8.2 The role of guidelines and algorithms in mRCC 156
8.3 Currently approved immunotherapies and targeted therapies 159
8.4 Treatment algorithms for the future 170
Conclusions 171
References 171

Conclusions 174
Bernard Escudier and Martin Gore

Abbreviations 176

Index 179